Skip to main content

Advertisement

SpringerLink
Log in

A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript

  • Clinical Trial Report
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS–FLI1 transcription factor. We conducted a phase I/II trial to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of mithramycin in children with refractory solid tumors, and the activity in children and adults with refractory Ewing sarcoma.

Patients and methods

Mithramycin was administered intravenously over 6 h once daily for 7 days for 28 day cycles. Adult patients (phase II) initially received mithramycin at the previously determined recommended dose of 25 µg/kg/dose. The planned starting dose for children (phase I) was 17.5 µg/kg/dose. Plasma samples were obtained for mithramycin PK analysis.

Results

The first two adult patients experienced reversible grade 4 alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation exceeding the MTD. Subsequent adult patients received mithramycin at 17.5 µg/kg/dose, and children at 13 µg/kg/dose with dexamethasone pretreatment. None of the four subsequent adult and two pediatric patients experienced cycle 1 DLT. No clinical responses were observed. The average maximal mithramycin plasma concentration in four patients was 17.8 ± 4.6 ng/mL. This is substantially below the sustained mithramycin concentrations ≥50 nmol/L required to suppress EWS–FLI1 transcriptional activity in preclinical studies. Due to inability to safely achieve the desired mithramycin exposure, the trial was closed to enrollment.

Conclusions

Hepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS–FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Esiashvili N, Goodman M, Marcus RB Jr (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 30:425–430. doi:10.1097/MPH.0b013e31816e22f3

    Article  PubMed  Google Scholar 

  2. Gaspar N et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046. doi:10.1200/JCO.2014.59.5256

    Article  CAS  PubMed  Google Scholar 

  3. Womer RB et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154. doi:10.1200/JCO.2011.41.5703

    Article  CAS  PubMed Central  Google Scholar 

  4. Delattre O et al (1994) The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331:294–299. doi:10.1056/NEJM199408043310503

    Article  CAS  PubMed  Google Scholar 

  5. Delattre O et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165. doi:10.1038/359162a0

    Article  CAS  PubMed  Google Scholar 

  6. Bailly RA et al (1994) DNA-binding and transcriptional activation properties of the EWS–FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14:3230–3241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kauer M et al (2009) A molecular function map of Ewing’s sarcoma. PLoS One 4:e5415. doi:10.1371/journal.pone.0005415

    Article  PubMed  PubMed Central  Google Scholar 

  8. Riggi N et al (2014) EWS–FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26:668–681. doi:10.1016/j.ccell.2014.10.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gangwal K et al (2008) Microsatellites as EWS/FLI response elements in Ewing’s sarcoma. Proc Natl Acad Sci USA 105:10149–10154. doi:10.1073/pnas.0801073105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Riggi N, Stamenkovic I (2007) The biology of Ewing sarcoma. Cancer Lett 254:1–10. doi:10.1016/j.canlet.2006.12.009

    Article  CAS  PubMed  Google Scholar 

  11. Hu-Lieskovan S et al (2005) EWS–FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res 65:4633–4644. doi:10.1158/0008-5472.CAN-04-2857

    Article  CAS  PubMed  Google Scholar 

  12. May WA et al (1997) EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 17:495–497. doi:10.1038/ng1297-495

    Article  CAS  PubMed  Google Scholar 

  13. Maksimenko A, Malvy C (2005) Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets 9:825–830. doi:10.1517/14728222.9.4.825

    Article  CAS  PubMed  Google Scholar 

  14. Grohar PJ et al (2011) Identification of an inhibitor of the EWS–FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103:962–978. doi:10.1093/jnci/djr156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mendiola M et al (2006) The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 118:1381–1389. doi:10.1002/ijc.21578

    Article  CAS  PubMed  Google Scholar 

  16. Kinsey M, Smith R, Lessnick SL (2006) NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma. Mol Cancer Res 4:851–859. doi:10.1158/1541-7786.MCR-06-0090

    Article  CAS  PubMed  Google Scholar 

  17. Nishimori H et al (2002) The Id2 gene is a novel target of transcriptional activation by EWS–ETS fusion proteins in Ewing family tumors. Oncogene 21:8302–8309. doi:10.1038/sj.onc.1206025

    Article  CAS  PubMed  Google Scholar 

  18. Osgood CL et al (2016) Identification of mithramycin analogues with improved targeting of the EWS–FLI1 transcription factor. Clin Cancer Res 22:4105–4118. doi:10.1158/1078-0432.CCR-15-2624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kofman S, Perlia CP, Economou SG (1973) Mithramycin in the treatment of metastatic Ewing’s sarcoma. Cancer 31:889–893

    Article  CAS  PubMed  Google Scholar 

  20. Kennedy BJ, Torkelson JL (1995) Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 24:327–328

    Article  CAS  PubMed  Google Scholar 

  21. Curreri AR, Ansfield FJ (1960) Mithramycin-human toxicology and preliminary therapeutic investigation. Cancer Chemother Rep 8:18–22

    CAS  Google Scholar 

  22. Spear PW (1963) Clinical trial with mithramycin. Cancer Chemother Rep 29:109–110

    CAS  Google Scholar 

  23. Mithramycin (mithracin) (1971) For intravenous use. Clin Pharmacol Ther 12:310–313

    Article  Google Scholar 

  24. Kofman S, Eisenstein R (1963) Mithramycin in the treatment of disseminated cancer. Cancer Chemother Rep 32:77–96

    CAS  PubMed  Google Scholar 

  25. Bilezikian JP (1992) Management of acute hypercalcemia. N Engl J Med 326:1196–1203. doi:10.1056/NEJM199204303261806

    Article  CAS  PubMed  Google Scholar 

  26. Perlia CP et al (1970) Mithramycin treatment of hypercalcemia. Cancer 25:389–394

    Article  CAS  PubMed  Google Scholar 

  27. Roth J et al (2014) Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 970:95–101. doi:10.1016/j.jchromb.2014.08.021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026

    Article  CAS  Google Scholar 

  29. Fraisse F, Marche C, Gibert C, Coquin Y, Vachon F (1980) Acute hepatic necrosis and hemorrhagic syndrome leading to a fatal outcome during treatment of hypercalcemia with mithramycin (author’s transl). Ann Med Interne (Paris) 131:281–284

    CAS  Google Scholar 

  30. Fang K et al (1992) Determination of plicamycin in plasma by radioimmunoassay. Ther Drug Monit 14:255–260

    Article  CAS  PubMed  Google Scholar 

  31. Grosso F et al (2006) Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 42:1484–1490. doi:10.1016/j.ejca.2006.02.010

    Article  CAS  PubMed  Google Scholar 

  32. Osgood CL et al (2016) 18F-FLT positron emission tomography (PET) is a pharmacodynamic marker for EWS–FLI1 activity and Ewing sarcoma. Sci Rep 6:33926. doi:10.1038/srep33926

    Article  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the patients and their families who participated in this trial, Linda Ellison-Dejewski for research nursing support, Natasha Brunson for assistance with data management, Dr. Seth Steinberg for assistance with the statistical design of the study, and Jeff Roth for technical support in the performance of pharmacokinetic assays.

Author information

Authors and Affiliations

  1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    Patrick J. Grohar, John Glod, Fernanda I. Arnaldez, Lauren Long, Patricia Whitcomb, Lee J. Helman & Brigitte C. Widemann

  2. Department of Pediatrics, Van Andel Research Institute, Helen DeVos Children’s Hospital, Michigan State University, East Lansing, USA

    Patrick J. Grohar & Tristan M. Sissung

  3. Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA

    Cody J. Peer & William D. Figg

Authors
  1. Patrick J. Grohar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Glod
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cody J. Peer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tristan M. Sissung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fernanda I. Arnaldez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lauren Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William D. Figg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patricia Whitcomb
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lee J. Helman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Brigitte C. Widemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Glod.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest relating to this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Patrick J. Grohar and John Glod Co first authors.

Lee J. Helman and Brigitte C. Widemann Co senior authors.

This work was supported in part by the Intramural Research Program of the Center for Cancer Research National Cancer Institute National Institutes of Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grohar, P.J., Glod, J., Peer, C.J. et al. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript. Cancer Chemother Pharmacol 80, 645–652 (2017). https://doi.org/10.1007/s00280-017-3382-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-017-3382-x

Keywords

Search

Navigation